Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01703949 · ClinicalTrials.gov registry record · Phase 2

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

A Phase 2 study of Refractory Non-Hodgkin Lymphoma and Recurrent Non-Hodgkin Lymphoma, sponsored by University of Washington.

Active
Registry status
Phase 2
Development phase
28
Enrollment target
1
Study location

NCT01703949 is a Phase 2 study of Refractory Non-Hodgkin Lymphoma and Recurrent Non-Hodgkin Lymphoma that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 28 participants, below the 95-participant average among 17 other Refractory Non-Hodgkin Lymphoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01703949, a Phase 2 study of Refractory Non-Hodgkin Lymphoma and Recurrent Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by University of Washington.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab works in treating patients with CD30+ lymphoma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as brentuximab vedotin, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as nivolumab may interfere with the ability of tumor cells to grow and spread. Giving brentuximab vedotin with or without nivolumab may work better in treating patients with CD30+ lymphoma.

Conditions Studied

Refractory Non-Hodgkin Lymphoma Recurrent Non-Hodgkin Lymphoma Refractory Hodgkin Lymphoma Recurrent Hodgkin Lymphoma

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Nivolumab
  • DRUG Brentuximab Vedotin

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2013-03-20
Est. Completion 2030-06-03
Phase Phase 2

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01703949

The ClinicalTrials.gov registry entry for NCT01703949 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 17 other Refractory Non-Hodgkin Lymphoma trials with a reported enrollment target (71% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Refractory Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT01703949 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT01703949 about?

NCT01703949 is a clinical study titled "Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma". This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab works in treating patients with CD30+ lymphoma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as brentuximab vedotin, may stimulate the immune syste...

What is the current status of trial NCT01703949?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2013-03-20. Estimated completion is 2030-06-03.

What conditions does trial NCT01703949 study?

This clinical trial studies the following conditions: Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma.

What interventions are being tested in trial NCT01703949?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL), Brentuximab Vedotin (DRUG).

Who is sponsoring clinical trial NCT01703949?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01703949 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Non-Hodgkin Lymphoma

All registered trials for this condition

Recurrent Non-Hodgkin Lymphoma

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.